Hexarelin Dosage Guide: Protocols, Desensitization, and Cycling

Hexarelin is a synthetic hexapeptide and one of the most potent ghrelin receptor agonists available. It shares structural similarities with GHRP-6 but produces a substantially stronger growth hormone (GH) pulse — often described as among the most powerful GH-releasing responses achievable with any GHRP compound. This potency is both its greatest advantage and its primary limitation, because it also comes with the most significant desensitization profile in the GHRP class.

Understanding how to use Hexarelin correctly — including dose selection, injection timing, and mandatory cycling — is essential for deriving lasting benefit from this peptide.

How Hexarelin Differs from Other GHRPs

All GHRPs work by binding to the ghrelin receptor (GHSR-1a), but Hexarelin has a uniquely high binding affinity that translates into a disproportionately large GH pulse relative to its dose. In head-to-head animal comparisons, Hexarelin consistently outperforms GHRP-6, GHRP-2, and Ipamorelin in peak GH elevation.

Hexarelin also has a secondary mechanism: direct stimulation of cardiac tissue through a distinct receptor pathway (the CD36 scavenger receptor). Early research suggests Hexarelin may have cardioprotective properties independent of GH, which has driven some clinical interest in its use for heart failure and cardiac ischemia recovery.

However, these same properties make Hexarelin's desensitization problem more pronounced. Continuous use leads to progressive downregulation of pituitary GHSR-1a receptors, resulting in meaningfully diminished GH pulses within 4–8 weeks of daily use.

Standard Dosage Range

• Low dose: 100 mcg per injection
• Standard dose: 150–200 mcg per injection
• Maximum recommended dose: 200 mcg per injection

Unlike GHRP-6, where the dose-response relationship extends to around 300 mcg, Hexarelin's potency means the effective ceiling is lower. Doses above 200 mcg per injection offer minimal additional GH release and only increase the risk of side effects and accelerate receptor desensitization.

Injection frequency: 2–3 times daily is standard, with the same fasted timing requirements that apply to all GHRPs:

• At least 2 hours after eating
• Wait 30–60 minutes before the next meal
• Morning fasted and pre-bed injections are the most productive slots

Desensitization: The Central Challenge of Hexarelin

Hexarelin's most important clinical characteristic is how rapidly it causes receptor desensitization. Research clearly demonstrates that continuous daily use leads to a predictable decline in the GH response:

• Weeks 1–3: Peak GH response, strong pulse with each injection
• Weeks 4–6: Noticeable reduction in GH pulse amplitude; some users report diminished subjective effects
• Weeks 6–8: Significant blunting of the GH response in most users; continued daily use offers diminishing returns

This pattern is well-documented in human clinical research. A study published in the European Journal of Endocrinology found that Hexarelin-induced GH release declined significantly after 16 weeks of continuous daily administration, with partial recovery following a 4-week washout period.

Importantly, the desensitization from Hexarelin appears to be at the pituitary receptor level (GHSR-1a downregulation), not at the hypothalamic level. A GHRH peptide administered after a Hexarelin washout period can still produce a robust GH pulse, indicating the underlying GH axis remains intact.

Cycling Protocol

The cycling protocol for Hexarelin is non-negotiable — unlike other peptides where cycling is a matter of optimization, with Hexarelin it is required to maintain efficacy.

Standard cycling protocol:

• On cycle: 4–6 weeks of daily use (2–3 injections per day)
• Off cycle: 4–6 weeks with no Hexarelin (use may continue with a non-desensitizing GHRP like Ipamorelin if desired)

Extended cycle option (for users who prioritize cardiac research protocols):

• 8 weeks on / 8 weeks off, accepting reduced GH efficacy in weeks 6–8 in exchange for a longer active period

Rotating protocol (advanced):

• Rotate Hexarelin, GHRP-6, and Ipamorelin across 4-week blocks
• This limits any single peptide's receptor engagement, reducing desensitization risk
• Maintain a GHRH peptide (e.g., Mod GRF 1-29) throughout for synergistic effect

During the off cycle, IGF-1 levels will gradually return toward baseline. Most users see meaningful recovery of the GH pulse within 4–6 weeks, with full recovery typically taking 8–10 weeks.

Stacking Hexarelin with a GHRH Peptide

As with all GHRPs, Hexarelin is significantly more effective when co-administered with a GHRH peptide. The synergistic amplification of the GH pulse when both pathways are activated simultaneously is well-established. For Hexarelin specifically, co-administration with Mod GRF 1-29 (100 mcg) can produce GH spikes that approach or exceed those of exogenous low-dose HGH.

Recommended GHRH partners:

• Mod GRF 1-29 / CJC-1295 without DAC: 100 mcg per injection, mixed in the same syringe as Hexarelin for convenience
• Sermorelin: A milder GHRH option with a strong safety record, suitable for older adults or those new to peptide therapy

Note: The desensitization concern applies only to Hexarelin, not to the GHRH co-peptide. If you take an off-cycle break from Hexarelin, you may continue GHRH administration to maintain partial GH support.

Hunger and Side Effects

Compared to GHRP-6, Hexarelin produces a more moderate hunger response. It still activates the ghrelin receptor and will increase appetite, but the hunger is generally less intense than with GHRP-6. Users transitioning from GHRP-6 to Hexarelin often report this as a welcome change.

Other notable side effects:

• Elevated prolactin and cortisol: Hexarelin is among the most prolactin- and cortisol-elevating GHRPs. At 200 mcg 3x daily, cortisol elevation can become significant enough to counteract some anabolic benefits. Dose and frequency reduction mitigates this.
• Water retention: Common in the first 2 weeks, typically resolves as the body adapts.
• Fatigue or sluggishness: Some users report lethargy, particularly at higher doses.
• Blood pressure considerations: Given Hexarelin's cardiac receptor activity, individuals with hypertension or pre-existing cardiac conditions should consult a physician before use.

Hexarelin for Cardiac Applications

Research interest in Hexarelin's non-GH cardiac effects has grown. Animal studies demonstrate that Hexarelin:

• Reduces infarct size following induced myocardial ischemia
• Attenuates cardiac fibrosis
• Improves ventricular function post-injury

These effects appear mediated by the CD36 receptor rather than GHSR-1a, meaning they persist even when GH desensitization occurs. This has led some researchers to propose Hexarelin as a potential adjunct therapy in post-MI recovery, though no human clinical trials have been completed.

For users interested in the cardiac benefits specifically, lower doses (50–100 mcg once daily) for longer cycles may be more appropriate than standard GH-optimization protocols.

Monitoring and Bloodwork

For users running Hexarelin cycles, the following lab markers are worth monitoring:

• IGF-1: Measure at baseline and after 4 weeks; will indicate whether meaningful GH pulse elevation is occurring
• Prolactin: Check if experiencing sexual side effects (libido changes, nipple sensitivity)
• Fasting glucose: GH elevation can transiently impair insulin sensitivity; relevant for pre-diabetic individuals
• Cortisol (AM): If fatigue is prominent, elevated cortisol from frequent high-dose use may be the cause

Frequently Asked Questions

Q: Is Hexarelin stronger than GHRP-6? Yes. Hexarelin produces a larger GH pulse at equivalent doses due to its higher binding affinity at GHSR-1a. This also means its desensitization profile is more pronounced, requiring stricter cycling.

Q: Can I use Hexarelin continuously for more than 8 weeks? It is not recommended. By weeks 6–8, most users experience significant blunting of the GH pulse. Continuous use beyond this point provides little GH benefit while still elevating cortisol and prolactin. An off-cycle break restores receptor sensitivity.

Q: What should I use during an off-cycle break from Hexarelin? Ipamorelin is the cleanest option — it maintains some GH pulse activity without accelerating further desensitization. Alternatively, use only a GHRH peptide (such as Mod GRF 1-29) during the washout to preserve some GH support.

Q: Does the desensitization from Hexarelin affect other GHRPs? Primarily yes — GHSR-1a downregulation reduces the response to all GHRPs to some extent. This is why rotating between different peptides and incorporating off-cycle periods is important for long-term GHRP users.

Q: How long until IGF-1 returns to baseline after stopping Hexarelin? IGF-1 typically returns to near-baseline within 3–4 weeks of stopping Hexarelin. The GH pulse response to re-challenge with Hexarelin recovers more slowly — usually 6–8 weeks for full receptor sensitivity restoration.

Q: Is Hexarelin suitable for anti-aging protocols? Yes, but with the caveat that cycling must be strictly observed. For anti-aging applications, a 4 weeks on / 8 weeks off cycle at 100 mcg twice daily is a conservative and sustainable approach. Pairing with a GHRH peptide maximizes the GH pulse during active weeks.